disclosure the basics of the canadian anticancer drug funding … · 2019-09-27 · 2019-09-27 2...
TRANSCRIPT
2019-09-27
1
The Basics of the Canadian Anticancer Drug Funding Process
Danica Wasney, B.Sc.Pharm., ACPR, BCOP
CancerCare Manitoba
Disclosure
• I have no conflict of interest to disclose
• I will receive an honorarium for development and delivery of this presentation from CAPhO
• This program has received no financial or in-kind support from any commercial or other organization
Question #1
• After confirming safety and efficacy is acceptable, which of the following is responsible for authorizing the sale of new oncology-hematology therapies in Canada?
A. CADTH (Canadian Agency for Drugs and Technology in Health)
B. Health Canada
C. pCODR (pan-Canadian Oncology Drug Review)
D. pCPA (pan-Canadian Pharmaceutical Alliance)
E. Drug manufacturer
Meet “CAPhOlizumab”• Humanized monoclonal antibody directed against PD-L1
• Administered as a flat dose of 100 mg intravenously over 30 minutes once every 4 weeks
• Currently being studied across multiple indications for use
• Trial results are now available for CAPhOlizumab vs. Standard of Care “Bananumab” in Resected Melanoma (Adjuvant therapy)
• Median RFS: 42 months (C) vs. 41 months (B)
• Toxicity: Immune-related Adverse Events: 32% (C) vs 37% (B)
• QOL: No significant differences between the two arms
• List Price: $15,000 per 100 mg dose
Objectives
1. Understand the processes used in Canada to consider a new oncology-hematology therapy for potential public funding.
2. Recognize the different roles and responsibilities of the organizations/individuals involved in oncology-hematology drug funding (e.g. Health Canada, CADTH, provincial cancer agencies, etc.).
3. Identify advantages and disadvantages to the present oncology-hematology drug funding processes in Canada.
4. Distinguish between the drug funding processes for anti-cancertherapies and supportive care therapies.
Definitions• Jurisdiction –province, territory, or federal (P/T/F); refers to the
“owner” of a drug program/budget; makes drug funding decisions
• Funding – refers to whether a drug plan/program provides coverage for eligible patients for a particular therapy/indication for use
• Reimbursement – may be used interchangeably with ”funding”; term used in CADTH recommendation documents created for jurisdictions
• Health Technology Assessment (HTA) – comprehensive assessment of the clinical and/or economic evidence for health technologies; evaluates benefits/consequences/value for money for a new intervention versus existing intervention; helps stakeholders make informed decisions
• Compassionate Access – supply of drug provided at no cost from a manufacturer for a therapy that does not have alternate funding sources (public or private insurance)
• Bridge Funding – often refers to the time between when a therapy is under review/recommended for reimbursement, but does not yet have public funding (e.g. is undergoing price negotiations)
1 2
3 4
5 6
2019-09-27
2
Acronyms of InterestAcronym Name Primary Role
CADTH Canadian Agency for Drugs and Technologies in Health Health Technology Assessment
pCODR pan-Canadian Oncology Drug Review (at CADTH; est 2011)Drug Reimbursement Recommendations (Hem-Onc)
CDR Common Drug Review (at CADTH) Drug Reimbursement Recommendations
INESSSInstitut national d’excellence en santé et en services sociaux (est. 2011)
HTA/Drug Reimbursement Recommendations (Quebec)
PAG Provincial Advisory Group (at pCODR) Drug Adoption and Implementation
pERC pCODR Expert Review Committee Drug Reimbursement Recommendations
pCPA pan-Canadian Pharmaceutical Alliance (est. 2010) Drug Contract Negotiations
NOC or NOC/c
Notice of Compliance; Notice of Compliance with conditionsApproval/authorization to market drug for a specific indication for use in Canada
PSP Patient Support Program Manufacturer-Sponsored Program providing access/bridge funding for emergent systemic therapies
Who Does What?
Health Canada
Regulatory (Effect & safety)
Nianda Penner
Who Does What?
Health Canada
Regulatory (Effect & safety)
CDR (CADTH)
pCODR (CADTH)
INESSS (Quebec)
HTA (Assess value)
Nianda Penner
Who Does What?
Health Canada
Regulatory (Effect & safety)
CDR (CADTH)
pCODR (CADTH)
INESSS (Quebec)
HTA (Assess value)
Pan Canadian Pharmaceutical Alliance (pCPA)
Price negotiator
Nianda Penner
Who Does What?
Health Canada
Regulatory (Effect & safety)
CDR (CADTH)
pCODR (CADTH)
INESSS (Quebec)
HTA (Assess value)
Pan Canadian Pharmaceutical Alliance (pCPA)
Price negotiator
F/P/T Ministries of Health
Decision maker/funder
Nianda Penner
The Road to Hematology-Oncology Drug Funding in Canada
7 8
9 10
11 12
2019-09-27
3
Clinical Benefit for New Drug/Indication
Clinical Benefit for New Drug/Indication
Health Canada Review for New Drug/Indication
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Manufacturer-Sponsored Patient Support Program
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
13 14
15 16
17 18
2019-09-27
4
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Manufacturer-Sponsored Patient Support Program
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Manufacturer-Sponsored Patient Support Program
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Positive* Recommendation
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Manufacturer-Sponsored Patient Support Program
pCPA Contract Negotiation
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Positive* Recommendation
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Manufacturer-Sponsored Patient Support Program
pCPA Contract Negotiation
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Positive* Recommendation
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Manufacturer-Sponsored Patient Support Program
pCPA Contract Negotiation
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Positive* Recommendation
Listing Agreement Completed
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Manufacturer-Sponsored Patient Support Program
pCPA Contract Negotiation
Health Canada Review for New Drug/Indication
Therapy Funded by Jurisdictions
NOC/NOCcreceived
Positive* Recommendation
Listing Agreement Completed
19 20
21 22
23 24
2019-09-27
5
Clinical Benefit – Clinical Trial Results
• New drug/therapy or existing drug/therapy for a new indication/combination shows:• Improved clinical outcomes vs. existing therapy
• Improved Progression-Free or Relapse-Free Survival• Improved Tolerability/Safety
• Improved Quality of Life/Patient Reported Outcome• Improved Overall Survival
• Ideally the comparator therapy in the clinical trial is relevant (i.e. used in Canada in this clinical situation)
Clinical Benefit - CAPhOlizumab
• Indication: Resected Melanoma
• Intervention: 100 mg IV every 4 weeks x 1 year (13 doses)
• Comparator: Bananumab 100 mg IV every 3 weeks x 1 year (18 doses) – For this case study, bananumab is funded and considered standard of care in Canada
• Recurrence-Free Survival: Non-significant difference (42 vs. 41 months)
• Toxicity: Appears slightly better tolerated for irAEs; no concerning safety signals identified to date via ADR reporting
• QOL: Non-significant difference vs. comparator therapy
• Manufacturer submits application to Health Canada for Notice of Compliance (NOC) and initiates Drug Review process with CADTH-pCODR (i.e. “pre-NOC”)
Clinical Benefit for New Drug/Indication
Clinical Benefit for New Drug/IndicationCAPhOlizumab
Clinical Benefit for New Drug/IndicationCAPhOlizumab✔️
Clinical Benefit for New Drug/Indication
Health Canada Review for New Drug/Indication
✔️
25 26
27 28
29 30
2019-09-27
6
Clinical Benefit for New Drug/Indication
Health Canada Review for New Drug/IndicationCAPhOlizumab
✔️Clinical Benefit for New
Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/IndicationCAPhOlizumab
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/IndicationCAPhOlizumab
CAPhOlizumab
✔️Clinical Benefit for New
Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/IndicationCAPhOlizumab
CAPhOlizumab
✔️
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
CAPhOlizumab
✔️
✔️
Health Canada Approval
• Regulatory step required before authorization to market a new drug or new indication for existing drug
• Evaluation efficacy and and safety based on submitted clinical data
• Health Canada may issue a:• Notice of Compliance (NOC)• Notice of Compliance, with conditions (NOC/c)• Notice of Deficiency
• NOC/c: authorization with the condition that the sponsor undertake additional studies to verify the clinical benefit
• NOC or NOC/c authorizes product for sale in Canada and for manufacturer to market product for sale only according to the approved indication(s) for use
31 32
33 34
35 36
2019-09-27
7
Health Canada• What does Health Canada approval of a drug mean?
• allows drug to be marketed and sold in Canada
• allows drug to be prescribed and used in Canada
• What does Health Canada approval of drug not mean?• does not mean that the drug is better than existing treatments
• does not mean that the drug is cost effective
• does not mean that the drug is covered by the federal, provincial or territorial public drug plans
Nianda Penner
Health Canada - CAPhOlizumab
• Notice of Compliance (NOC) issued for Resected Melanoma
• While CAPhOlizumab is under review by CADTH-pCODR, the Manufacturer opens a Patient Support Program (PSP) for physicians and patients
• This allows for interim access to CAPhOlizumab for Resected Melanoma while the CADTH-pCODR review process continues
• As CAPhOlizumab only has NOC for Resected Melanoma, the PSP will not provide CAPhOlizumab for other indications for use
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
CAPhOlizumab
✔️
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
CAPhOlizumab
✔️
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
CAPhOlizumab
NOC/NOCcreceived
✔️
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
CAPhOlizumab
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
✔️
✔️
37 38
39 40
41 42
2019-09-27
8
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
CAPhOlizumab
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
CAPhOlizumab
✔️
✔️Question #2
• How does CAPhOlizumab show better value versus its comparator therapies?
A. Less Frequent Administration
B. Improved Survival
C. Improved Tolerability
D. Lower Cost
E. All of the above
F. A and C only
Health Technology Assessment (HTA)
• Comparative evaluation of new therapy to existing therapies to determine overall value of the new intervention over existing• Encompasses clinical, economic, patient and resource use factors
• Value is not the same as price
• Determining value includes an assessment of cost, quality, and sustainability of a particular intervention compared to an alternative• What is the cost of the drug, health system resource use, adverse effects?
• Does this meet expectations and/or requirements? How or how not?
• Can we implement this? Can we afford this?
• Is there a trade off for using this instead of something else?
HTA in Canada for Hematology-Oncology:CADTH-pCODR
• pCODR evaluates new hematology-oncology drugs and/or new indications for existing hematology-oncology drugs
• Independent, not-for-profit organization; established by P/T/F jurisdictions in 2011 (after iJODR from 2007-2011)
• Mandate: Provide objective evidence and recommendations to jurisdiction to help make informed decisions about the optimal use of drugs
• Review process involves multiple stakeholders, with the aim to include the spectrum of those involved with cancer treatments
pCODR Review Process in Brief
Provincial Advisory Group
Sponsor
Patient Advocacy Group
Registered Clinician
Review Team
Registered Clinician
Provincial Advisory Group
Patient Advocacy Group
pCODR Expert Review Committee
Sponsor
INPUT
SUBMISSION
REVIEW
DELIBERATIONS
FEEDBACK
Initial Recommendation
Final Recommendation
Review Team:•Clinical Guidance Panel•Economic Guidance Panel•Health Research Methodologist
Helen Mai, pCODR-CADTH
pCODR Expert Review Committee
➢Purpose: “to make cancer drug funding recommendations to participating provincial/territorial Ministries of Health, provincial cancer agencies and federal drug programs that can be used by these jurisdictions to guide their cancer drug funding decisions. The pERC recommendations must consider the evidence-based reviews of the clinical effectiveness and cost effectiveness of cancer drug products conducted by pCODR and the input provided by patient advocacy groups and jurisdictions.”
➢Multidisciplinary committee comprised of the following members:➢6-8 cancer specialists (oncologists/hematologists)➢1 “non-oncology” physician➢3 health economists➢1-2 pharmacists➢2 patient representatives and 1 patient representative alternate➢At least one member must have expertise in health ethics
43 44
45 46
47 48
2019-09-27
9
pCODR’s (pERC) Deliberative Framework
Clinical Benefit• Effectiveness• Safety• Burden of Illness• Need
pCODR’s (pERC) Deliberative Framework
Clinical Benefit• Effectiveness• Safety• Burden of Illness• Need
Patient Values
pCODR’s (pERC) Deliberative Framework
Clinical Benefit• Effectiveness• Safety• Burden of Illness• Need
Patient Values
Economic Evaluation
Adoption Feasibility
• Economic feasibility• Organizational feasibility
pCODR’s (pERC) Deliberative Framework
Clinical Benefit• Effectiveness• Safety• Burden of Illness• Need
Patient Values
Economic Evaluation
pCODR Provincial Advisory Group (PAG)
• PAG consists of representatives from the provincial and territorial ministries of health, provincial cancer agencies, federal drug programs participating in CADTH programs and services, a representative from CAPCA, physicians and an ethicist.
• PAG provides input to CADTH to ensure that pERC recommendations address local needs and issues
• PAG members consider all issues related to implementation of recommendations
• Implementation of a new therapy may be complicated by issues such as:• sequencing of therapies,
• dose schedule variations (mg/kg vs. flat dose),
• missing clinical information (i.e. short-term follow-up, unknown duration of treatment)
Provincial Advisory Group (PAG)• In 2019, the role of PAG has expanded to involve more input and earlier in the
pCODR review process• Identifying potential issues or outcomes if a new therapy/indication receives a positive
reimbursement recommendation
• “Provisional Algorithms” are being developed and integrated into pCODR reviews• What would the systemic treatment of this disease/stage/therapeutic target look like if the
therapy receives a positive recommendation?’
• PAG members identify individual expert clinicians to support the development of this provisional algorithm and provide feedback on the algorithm as related to potential implementation
• PAG members continue to facilitate consultation and information exchange between their respective jurisdictions and CADTH, including important trends in the development and utilization of cancer drugs, and significant issues relevant to their assessment.
https://www.cadth.ca/sites/default/files/pcodr/pCODR-provincial-advisory-group-terms-of-reference.pdf
49 50
51 52
53 54
2019-09-27
10
HTA - CAPhOlizumabCompared to existing therapies, CAPhOlizumab provides advantages:
• Less frequent administration• Fewer visits for the patient• Fewer pharmacy admixtures• Less chair time in treatment• Fewer clinic visits with prescriber• Fewer blood tests
• May have a different or slightly better safety profile than existing therapies
• Not a new patient population – this group is already receiving treatment
• Not an “add on” therapy - this would be a replacement to bananumab
HTA - CAPhOlizumab
Compared to existing therapies, CAPhOlizumab appears neutral:
• Clinical outcomes • Recurrence-free survival• Safety• Quality of Life
• List price of CAPhOlizumab vs. Bananumab ($15,000 x 13 is equivalent to $10,833 x 18; $195,000 per patient)• Note: Cost-effectiveness of CAPhOlizumab is not worse than Bananumab BUT that is
misleading about whether CAPhOlizumab provides value; the economic analysis will evaluate the differences in costs and the differences in effects between options; no long term outcomes (e.g. Overall Survival) have been reported yet so it is difficult to know if there is a difference in effect between B or C; price of one year of treatment is the same (and both options are very expensive)
HTA - CAPhOlizumab
Compared to existing therapies, CAPhOlizumab provides disadvantages:
• ”Me too” agent in this clinical space
• Resources would be required to implement this therapy• pCPA contract negotiation• Education for patients/caregivers, and health care providers (HCPs)• Systemic Therapy administration, preparation, and monitoring tools for HCPs
• May not provide improved value for money versus existing alternatives• “Opportunity Cost” – trade off – health system resource use to provide this as
an option
• Budget impact would be very high, even with limited numbers of eligible patients ($158,400 per patient)
pERC Recommendation - CAPhOlizumab
• “Conditionally recommends reimbursement if the following conditions are met…• The public drug plan cost of CAPhOlizumab should not exceed the public drug plan
cost of other available immune checkpoint inhibitors.
• Feasibility of adoption is addressed (budget impact).”
• Note: pERC did not make a condition of “improving cost-effectiveness to an acceptable level” because bananumab was used as the comparator in the economic analysis (not placebo).
• Based on the “conditionally positive” recommendation, pCPAnegotiation process begins
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
CAPhOlizumab
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
CAPhOlizumab
✔️
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
CAPhOlizumab
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
CAPhOlizumab
✔️
✔️
55 56
57 58
59 60
2019-09-27
11
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
CAPhOlizumab
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
CAPhOlizumab
✔️
✔️
Positive* Recommendation
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
CAPhOlizumab
CAPhOlizumab
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
CAPhOlizumab
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
CAPhOlizumab
CAPhOlizumab
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
CAPhOlizumab
CAPhOlizumab
✔️
Question #3
• For what type of medications does pCPA coordinate drug negotiations?
A. Parenteral anti-cancer agents
B. Oral anti-cancer agents
C. Supportive care agents
D. Non-oncology prescription agents
E. A and B only
F. All of the above
61 62
63 64
65 66
2019-09-27
12
Pan-Canadian Pharmaceutical Alliance (pCPA)• “Conducts joint provincial/territorial/federal negotiations for brand name
and generic drugs in Canada to achieve greater value for publicly funded drug programs and patients through the use of the combined negotiating power of participating jurisdictions”.
• The pCPA member jurisdictions include public drug plan and/or cancer agency participation from: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Québec, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland & Labrador, Yukon, Northwest Territories, Non-Insured Health Benefits (NIHB), Correctional Services of Canada (CSC) and Veterans Affairs Canada (VAC).
• pCPA mandate is to enhance patient access to clinically relevant and cost-effective drug treatment options. It serves this mandate by conducting collective, expert-informed negotiations for drugs.
http://www.canadaspremiers.ca/pan-canadian-pharmaceutical-alliance/
Pan-Canadian Pharmaceutical Alliance (pCPA)• pCPA Office coordinates the negotiation process; PAG members
participate in negotiations with Manufacturers
• Negotiation will involve a review of the issues identified in the pERC recommendation, including any conditions outlined
• When an agreement is reached, a Listing Agreement is available for participation jurisdictions • Includes specific wording on the eligible patient population
• Any modifications to the list price of a drug that were the result of negotiations are kept strictly confidential
• Once the listing agreement signed, jurisdictions have a contract with the manufacturer, subject to renegotiation after expiry
Back to CAPhOlizumab• During the negotiation process, the Manufacturer continued to
provide bridge funding for CAPhOlizumab via the Patient Support Program
• Negotiations between the Manufacturer and pCPA representatives took 5 months to complete – a Listing Agreement is now signed by your jurisdiction
• After completing the Listing Agreement, the Manufacturer announces the Patient Support Program will close once public funding is available
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
CAPhOlizumab
CAPhOlizumab
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
CAPhOlizumab
CAPhOlizumab
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
CAPhOlizumab
CAPhOlizumab
✔️
Listing Agreement Completed
67 68
69 70
71 72
2019-09-27
13
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
CAPhOlizumab
✔️
Listing Agreement Completed
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
CAPhOlizumab
✔️
Listing Agreement Completed
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
✔️
Listing Agreement Completed
✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
✔️
Listing Agreement Completed
✔️✔️
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
✔️
Listing Agreement Completed
✔️✔️
CAPhOlizumab
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Health Canada Review for New Drug/Indication
NOC/NOCcreceived
Manufacturer-Sponsored Patient Support Program
Positive* Recommendation
pCPA Contract Negotiation
✔️
✔️
✔️
Listing Agreement Completed
✔️✔️
Therapy Funded by Jurisdictions
CAPhOlizumab
73 74
75 76
77 78
2019-09-27
14
Differences by Route and Treatment Intent
• Oral vs. Parenteral administration
• Active Cancer Therapy vs. Supportive Care
The Road to Hematology-Oncology Drug Funding in Canada – Oral Agents
Clinical Benefit for New Drug/Indication
CADTH-pCODR Process
Manufacturer-Sponsored Patient Support Program
pCPA Contract Negotiation
Health Canada Review for New Drug/Indication
Therapy Funded by Jurisdictions
NOC/NOCcreceived
Positive* Recommendation
Listing Agreement Completed
Anticancer Drug Funding In Canada
Hospital Cancer Agency Provincial Drug Plan
BCX
(oral and intravenous)
ABX
(oral and intravenous)
SKX
(oral and intravenous)
MBX
(intravenous)X
(oral)
ONX
(intravenous drugspre-2005)
X(intravenous drugs
post-2005)
X(oral)
NBX
(intravenous)X
(oral)
NSX
(intravenous)X
(oral)
NLX
(intravenous)X
(oral)
PEIX
(intravenous)X
(oral)
Oral Anticancer Agents• Same regulatory process as parenteral agents (Health Canada)
• Same drug review process as parenteral agents (CADTH-pCODR)
• Same contracting process as parenteral agents (pCPA)
• Same or Different drug budgets from parenteral agents• Variable by jurisdiction• Budget may be administered by Cancer Agencies vs. Provincial Drug Plans
(”centralized” vs. “de-centralized”)• Private insurance involved to differing extents depending upon funding model
• CancerCare Ontario Guideline – April 25, 2019:
• https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full/1_CCO_THCD_Report_25Apr2019.pdf
• ***Appendix B (p.59-70) – Jurisdictional Scan – Key Features of Different Models for Take-Home Cancer Drugs
The Road to Drug Funding in Canada –Supportive Care Agents
79 80
81 82
83 84
2019-09-27
15
Clinical Benefit for New Drug/Indication
CADTH--CDR Process
Manufacturer-Sponsored Patient Support Program
pCPA Contract Negotiation
Health Canada Review for New Drug/Indication
Therapy Funded by Jurisdictions
NOC/NOCcreceived
Positive* Recommendation
Listing Agreement Completed
Clinical Benefit for New Drug/Indication
CADTH--CDR Process
Manufacturer-Sponsored Patient Support Program
pCPA Contract Negotiation
Health Canada Review for New Drug/Indication
Therapy Funded by Jurisdictions
NOC/NOCcreceived
Positive* Recommendation
Listing Agreement Completed
Clinical Benefit for New Drug/Indication
CADTH--CDR Process
Manufacturer-Sponsored Patient Support Program
pCPA Contract Negotiation
Health Canada Review for New Drug/Indication
Therapy Funded by Jurisdictions
NOC/NOCcreceived
Positive* Recommendation
Listing Agreement Completed
Supportive Care Agents
• Same regulatory process as parenteral agents (Health Canada)
• Different drug review process as parenteral agents (CADTH-pCODR)
• Same contracting process as parenteral agents (pCPA)
• Same and/or Different drug budgets from anticancer agents• Variable by jurisdiction
• Budget may be administered by Cancer Agencies vs. Provincial Drug Plans (”centralized” vs. “de-centralized”)
• Private insurance involved to differing extents depending upon funding model
ProviderAnticancer –Parenteral Agents
Anticancer – Oral Agents
Supportive Care –Parenteral Agents
Supportive Care –Oral Agents
Regulatory Approval Health Canada Health Canada Health Canada Health Canada
HTA pCODR pCODR CDR CDR
Drug contracting pCPA pCPA pCPA pCPA
Drug FundingCancer Agency ORTreatment Hospital
Cancer Agency ORTake Home Drug Program
Cancer Agency OR Treatment Facility
Take Home Drug Program OR Treatment Facility
Bird’s Eye View Public Funding is Generally Not Available When…
• Therapy does not have Notice of Compliance• Special Access Programme may release in exceptional cases
• “Do Not Reimburse” (aka Negative) recommendation from HTA organization• No pCPA negotiation will proceed• Jurisdictions will not pursue a listing agreement/list on drug program formulary
• New indication/combination for existing therapy has not completed the drug review process
• Listing Agreement cannot be reached• A conditional recommendation is issued by HTA organization• Parties cannot arrive at agreement
85 86
87 88
89 90
2019-09-27
16
Advantages to our Processes as of 2019
• pan-Canadian: drug reviews and price negotiations are harmonized wherever possible
• Consistent, thorough: Extensive and standardized review process; standardized listing agreements (eligible patient population)
• Collaborative: Incorporates clinical, economic, patient, and implementation factors in recommendation process and involves multiple jurisdictions and stakeholders
• Improved efficiencies: Reduced replication of effort by jurisdictions
Disadvantages to our Processes as of 2019
• Fractures remain: Differences in parenteral vs. oral anticancer drug budgets increases complexities for patients, caregivers, pharmacy staff
• Clinical data gaps: Implementation issues often expose where new drugs may be difficult to incorporate into existing treatment algorithms
• Limits to capacity and resources: number of new drugs/new indications is burgeoning; access to Patient Support Programs may assist with drug access, but has resource implications of its own; Drug Access Navigators are not available in every jurisdiction
• Prioritization and Sustainability- Need to balance of best evidence with feasibility and capacity in current climate; how do we prioritize our efforts in a fair, equitable, appropriate way?
Thank you for attending
Questions?
91 92
93